SPY433.72-8.92 -2.02%
DIA342.92-5.69 -1.63%
IXIC14,546.68-423.29 -2.83%

Pfizer starts dosing patients in oral COVID-19 drug trial

Pfizer starts dosing patients in oral COVID-19 drug trial

reuters.com · 09/01/2021 08:05
Pfizer starts dosing patients in oral COVID-19 drug trial

- Pfizer Inc PFE.N said on Wednesday it had started dosing in a mid-to-late-stage trial of its oral antiviral therapy for COVID-19 in non-hospitalized, symptomatic adult patients.

The company and its rivals, including U.S.-based Merck & Co Inc MRK.N and Swiss pharmaceutical Roche Holding AG ROG.S, have been racing to develop the first antiviral pill to be taken on early signs of the illness.

Pfizer's mid-to-late-stage trial in 1,140 participants would study the therapy, PF-07321332, in combination with a low dose of ritonavir, which has been used with other antivirals too, the company said. (https://bit.ly/3kJWzg9)

PF-07321332 is designed to block the activity of a key enzyme that is needed for the coronavirus to replicate.

To date, Gilead Sciences Inc's GILD.O remdesivir, administered intravenously, is the only approved antiviral treatment for COVID-19 in the United States.

Merck and partner Ridgeback Biotherapeutics' molnupiravir is already being studied in a late-stage trial in non-hospitalized patients to see if it reduces the risk of hospitalization or death.

The companies said on Wednesday they had started a late-stage trial of molnupiravir for the prevention of COVID-19 infection.

Pfizer said in July if the PF-07321332 trial was successful, it would file for a potential emergency use authorization in the fourth quarter.



(Reporting by Amruta Khandekar;
Editing by Vinay Dwivedi)

((Amruta.Khandekar@thomsonreuters.com;))